-
-
-
-
-
-
-
J&J's Tremfya shows sustained remission in Crohn's at 3 years
-
-
-
-
-
-
-
Johnson & Johnson (JNJ) call put ratio 1.6 calls to 1 put into quarter results
-
-
-
-
-
-
-
J&J lung cancer drug combo shows low side effect rates in study
-
-
-
-
-
-
-
Morgan Stanley tracks US drug market prescriptions for week ending July 31
-
-
-
-
-
-
-
FDA clears Johnson & Johnson's Ottava robotic surgical system
-
-
-
-
-
-
-
Johnson & Johnson (JNJ) call put ratio 1.5 calls to 1 put into quarter results
-
-
-
-
-
-
-
Johnson & Johnson to stay out of obesity drugs, focus on cancer, CEO says
-
479,787 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


